Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Inflammatory Bowel Disease

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Inflamm Bowel Dis.

Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A

doi: 10.1097/

Inflammatory Bowel Disease

Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients

Scand J Gastroenterol.

Everhov ÅH, Sachs MC, Malmborg P, Nordenvall C, Myrelid P, Khalili H, Elmberg M, Ekbom A, Askling J, Jakobsson G, Halfvarson J, Ludvigsson JF, Olén O

doi: 10.1080/00365521.

Inflammatory Bowel Disease

Treatment of Inflammatory Bowel Disease in the Older Patient

Inflamm Bowel Dis.

Dorreen A, Heisler C, Jones J

doi: 10.1093/ibd/izy023.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Inflamm Bowel Dis.

Lin SC, Goldowsky A, Papamichael K, Cheifetz AS

doi: 10.1093/ibd/izy376.

Inflammatory Bowel Disease

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study

United European Gastroenterol J.

Goren I, Brom A, Yanai H, Dagan A, Segal G, Israel A

doi: 10.1177/2050640619874524.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

RECOMMENDED

Inflammatory Bowel Disease

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

doi: 10.1111/jgh.14563.

Inflammatory Bowel Disease

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study

J Pediatr Gastroenterol Nutr.

Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S

doi: 10.1097/MPG.

Related content

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial

Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients

Treatment of Inflammatory Bowel Disease in the Older Patient

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9-year cohort study

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study